Global law firm Dentons advised the Board of Directors and shareholders of VRmagic on the sale of 77 percent of their shares in the company to the Swiss medical technology company Haag-Streit.
VRmagic was founded in 2001 and is a pioneer in virtual and augmented reality technology for medical training. The solutions developed by VRmagic enable realistic simulation of examinations and operations on the eye. The company has special expertise in the development of camera systems for high-precision optical tracking. With its Eyesi® product group, VRmagic is the market leader in the training of ophthalmologists.
With this acquisition, Haag-Streit is expanding its ophthalmology product portfolio in the key area of medical training. The transaction follows a four-year collaboration between the two companies to develop a simulator for slit lamp examinations, an important instrument for microscopic examination of the human eye.
A Dentons team led by partner Robert Bastian advised the Executive Board and the shareholders of VRmagic on the sale. Bastian has advised the company's largest shareholder Leonardo Venture on numerous transactions over the past few years.
Advisors to VRmagic’s management and shareholders
Dentons (Frankfurt): Robert Bastian (Lead Partner, Corporate/M&A), Thomas Voss (Partner, Tax)